Literature DB >> 26542155

[Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

M Lambert1, C Correll2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26542155     DOI: 10.1007/s00115-015-4427-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  36 in total

1.  A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia.

Authors:  Tyler A Lesh; Costin Tanase; Benjamin R Geib; Tara A Niendam; Jong H Yoon; Michael J Minzenberg; J Daniel Ragland; Marjorie Solomon; Cameron S Carter
Journal:  JAMA Psychiatry       Date:  2015-03       Impact factor: 21.596

2.  Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial.

Authors:  Naohisa Tsujino; Takahiro Nemoto; Keiko Morita; Naoyuki Katagiri; Shinya Ito; Masafumi Mizuno
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-12-24       Impact factor: 2.582

3.  Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.

Authors:  Scott W Woods; Alan Breier; Robert B Zipursky; Diana O Perkins; Jean Addington; Tandy J Miller; Keith A Hawkins; Eva Marquez; Stacy R Lindborg; Mauricio Tohen; Thomas H McGlashan
Journal:  Biol Psychiatry       Date:  2003-08-15       Impact factor: 13.382

4.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

5.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics.

Authors:  Lisa J Phillips; Barnaby Nelson; Hok Pan Yuen; Shona M Francey; Magenta Simmons; Carrie Stanford; Margaret Ross; Daniel Kelly; Kathryn Baker; Philippe Conus; Paul Amminger; Francois Trumpler; Yang Yun; Michelle Lim; Catharine McNab; Alison R Yung; Patrick D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2009-09       Impact factor: 5.744

Review 6.  Longitudinal studies of cognition in schizophrenia: meta-analysis.

Authors:  Andrei Szöke; Anca Trandafir; Marie-Estelle Dupont; Alexandre Méary; Franck Schürhoff; Marion Leboyer
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

7.  Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state.

Authors:  Hiroyuki Kobayashi; Keiko Morita; Kiyoaki Takeshi; Hiroki Koshikawa; Ryoko Yamazawa; Haruo Kashima; Masafumi Mizuno
Journal:  J Clin Psychopharmacol       Date:  2009-10       Impact factor: 3.153

8.  Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.

Authors:  Anissa Abi-Dargham; Elsmarieke van de Giessen; Mark Slifstein; Lawrence S Kegeles; Marc Laruelle
Journal:  Biol Psychiatry       Date:  2009-01-23       Impact factor: 13.382

9.  Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.

Authors:  Oliver D Howes; Subrata K Bose; Federico Turkheimer; Isabel Valli; Alice Egerton; Lucia R Valmaggia; Robin M Murray; Philip McGuire
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

10.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

View more
  1 in total

1.  [Pros and cons of antipsychotic drugs in Prodromal stages of schizophrenia].

Authors:  S Weinmann; V Aderhold
Journal:  Nervenarzt       Date:  2017-09       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.